Day: March 18, 2022

Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences

Written by Customer Service on March 18, 2022. Posted in Public Companies.

– 5th Annual Neuroscience Innovation Forum – – BIO-Europe Spring® 2022 – CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in March and invites investors to participate in virtual one-on-one meetings. Please see additional details below:5th Annual Neuroscience Innovation Forum (NIF) – Registration Link Panel: Advances in Neuropsychiatry Panel Wednesday, March 23rd at 9:00am ET Corporate...

HTG Molecular Diagnostics Announces $7.5 Million Private Placement

Written by Customer Service on March 18, 2022. Posted in Public Companies.

TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to HTG from the private placement, before deducting the placement agent fees and other estimated fees and expenses related to the private placement, are expected to be approximately $7.5 million. HTG intends to use the net proceeds from the private placement for working capital and general corporate purposes. Pursuant to the terms of the securities purchase agreement, HTG will issue 3,244,987 units at a price of $2.312 per unit to the investor (less $0.001 for each pre-funded...

Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO’s Breast Cancer Congress 2022

Written by Customer Service on March 18, 2022. Posted in Public Companies.

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from its Phase IIb AIPAC trial at ESMO’s Breast Cancer Congress 2022, which will take place onsite in Berlin, Germany and virtually on 3-5 May 2022. Immutep’s AIPAC trial evaluated its lead product candidate eftilagimod alpha (“efti”) in combination with paclitaxel chemotherapy in 227 patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC). Final Overall Survival results were reported in November 2021. The Company will announce the new biomarker and multivariate analysis data to the market and make the poster available on its website. The European Society for Medical Oncology (ESMO) is the the leading professional...

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

Written by Customer Service on March 18, 2022. Posted in Public Companies.

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office. This new Japanese patent was filed as a divisional application and follows the grant of the parent Japanese patent announced in 2019. Corresponding patents in this family have been granted in other territories including Australia, China, Europe and the United States, as announced in 2018 through 2021. The claims of the patent are directed to pharmaceutical compositions for use in the treatment of cancer, where the composition comprises LAG525 in a specific dose and for use in a defined treatment regimen. The compositions may also be administered in combination...

Bionano Genomics Announces Publication of Comprehensive Validation of Optical Genome Mapping for Hematologic Neoplasms

Written by Customer Service on March 18, 2022. Posted in Public Companies.

Key findings from evaluation of 59 Heme Samples and 10 Controls:OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases OGM Sensitivity: 98.7% OGM Specificity: 100% Positive Predictive Value: 100% Negative Predictive Value: 98% OGM Accuracy: 99.2% First-Pass Success Rate: 100% Limit of Detection (LOD) for aneuploidies, translocations, interstitial deletions and duplications at 400X: 5% variant allele fractionSAN DIEGO, March 18, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the publication...

The Finnish Financial Supervisory Authority has approved a supplement to the Finnish language Merger Prospectus prepared for the merger of the remaining Evli and Fellow Finance Plc

Written by Customer Service on March 18, 2022. Posted in Public Companies.

EVLI BANK PLC STOCK EXCHANGE RELEASE 18 MARCH 2022 AT 2.00 PM (EET/EEST) NOT FOR PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA OR SINGAPORE, NEW ZEALAND, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE COMPLETED OR REGISTERED OR REQUIRE ANY MEASURE TO BE UNDERTAKEN IN ADDITION TO THE REQUIREMENTS UNDER FINNISH LAW. SEE “IMPORTANT NOTICE” BELOW.THE FINNISH FINANCIAL SUPERVISORY AUTHORITY HAS APPROVED A SUPPLEMENT TO THE FINNISH LANGUAGE MERGER PROSPECTUS PREPARED FOR THE MERGER OF THE REMAINING EVLI AND FELLOW FINANCE PLC The Finnish Financial Supervisory Authority has today on 18 March 2022, approved a supplement to the Finnish language...

Barrick Set to Deliver Substantial Future Free Cash Flows

Written by Customer Service on March 18, 2022. Posted in Public Companies.

All amounts expressed in US dollars unless stated otherwise TORONTO, March 18, 2022 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) is built on a foundation of six Tier One1 gold mines with rolling 10-year plans which secure the company’s ability to generate substantial free cash flows2 for the next decade and beyond, says executive chairman John Thornton. Writing in the company’s 2021 annual report, published today, Thornton notes that in September 2018, when the Randgold merger was announced, Barrick had net debt in excess of $4 billion. Since then it has not only moved into a net cash position but has returned $2.5 billion of cash to shareholders, including last year’s record distribution of $1.4 billion. “As previously announced, after careful consideration of our capital allocation, the board has settled on...

Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris

Written by Customer Service on March 18, 2022. Posted in Public Companies.

Sanofi moves forward with EUROAPI listing on Euronext ParisSanofi will give its shareholders the opportunity to be part of EUROAPI’s new chapter of growth through an additional extraordinary dividend in kind EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions The French State, through the fund French Tech Souveraineté, intends to acquire 12% of EUROAPI’s capital for up to €150 million from Sanofi to become a long-term reference shareholder of EUROAPI As planned, Sanofi will continue to hold circa 30% of EUROAPI, post transaction The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPI’s French prospectusParis, March 18 2022. Today marks a major milestone for EUROAPI, a leading European company dedicated to the development, production...

Telesat Reports Results for the Quarter and Year Ended December 31, 2021

Written by Customer Service on March 18, 2022. Posted in Earnings Releases And Operating Results.

OTTAWA, March 18, 2022 (GLOBE NEWSWIRE) — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three-month and one-year periods ended December 31, 2021. All amounts are in Canadian dollars and reported under International Financial Reporting Standards (“IFRS”) unless otherwise noted. “I am pleased to report our 2021 fourth quarter and full year results as a dual-listed, public company,” commented Dan Goldberg, Telesat’s President and CEO. “Despite modestly lower year-over-year revenues and Adjusted EBITDA, adjusted for foreign exchange rate changes, Telesat continued to generate strong cash flows, ending the year with over $1.4 billion in cash. We also continued to deliver industry-leading Adjusted EBITDA margins1 with high capacity utilization...

Wellbeing Digital Sciences Reports Financial Results for the Second Fiscal Quarter of 2022

Written by Customer Service on March 18, 2022. Posted in Earnings Releases And Operating Results.

Revenue Exceeded $1.6 Million for the Period Ended January 31, 2022 VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) — Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that it has filed its financial results for the quarter ended January 31, 2022, which is the second quarter of the Company’s 2022 fiscal year ending July 31, 2022, the highlights of which are included in this news release. The full set of Consolidated Financial Statements and Management Discussion and Analysis can be viewed by visiting the Company’s website at www.wellbeingdigital.co or its profile page on SEDAR at www.sedar.com. Financial...

Day: March 18, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice